pharmaphorum September 5, 2024
Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.
The biotech focuses on trawling the 98% of human genetic material, sometimes called the dark genome or ‘junk’ DNA, that is not involved in the expression of RNA and proteins. In recent years, it has been shown to be a rich and largely untapped source of drug targets.
Lilly has formed a multi-year collaboration with Haya to use its RNA-guided regulatory genome platform to support its preclinical drug discovery efforts in obesity and related metabolic conditions like diabetes.
It is the first big biopharma group to tap into Haya’s platform, which identifies...
Today's Sponsors
Today's Sponsor